Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 21 Feb 2023
First gene therapy for haemophilia B, CSL's Hemgenix, approved by the European Commission
20 February 2023 - Hemgenix underscores CSL's promise to deliver life-changing innovations that have the potential to help patients lead ...
Posted by Michael Wonder on 21 Feb 2023
Lutetium Lu 177 vipivotide tetraxetan for the treatment of adults with PSMA positive hormone-relapsed metastatic prostate cancer after two or more therapies
21 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 21 Feb 2023
Rimegepant sulphate for the treatment or prevention of migraine
21 February 2023 - The Department of Health and Social Care has NICE to produce guidance on the use of rimegepant ...
Posted by Michael Wonder on 21 Feb 2023
PHARMAC signals first step towards funding continuous glucose monitors
21 February 2023 - PHARMAC will soon be seeking competitive commercial offers for the supply of funded continuous glucose monitors ...
Posted by Michael Wonder on 21 Feb 2023
PHARMAC's communications approach for the Trikafta consultation
21 February 2023 - To be transparent about its approach, PHARMAC has released information, including a communications plan and correspondence ...
Posted by Michael Wonder on 20 Feb 2023
Improve ventilation and make antiviral drug widely available, long COVID inquiry hears
20 February 2023 - GPs say they are unable to properly care for the hundreds of thousands of Australians with ...
Posted by Michael Wonder on 20 Feb 2023
Medicare annual statistics – rolling 12 months (July 2009 to December 2022)
20 February 2023 - This document presents rolling 12 month Medicare statistics by three variables ...
Posted by Michael Wonder on 20 Feb 2023
EMA publishes agenda for 20-23 February 2023 CHMP meeting
20 February 2023 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 20 Feb 2023
‘Caught in the middle’: A battle between Vertex and insurers is leaving cystic fibrosis patients with crushing drug costs
20 February 2023 - Dan Brickey was stunned when he learned the news. ...
Posted by Michael Wonder on 20 Feb 2023
ABPI response to Lord O'Shaughnessy review
20 February 2023 - The Office for Life Sciences has today announced that Lord James O’Shaughnessy will conduct a review ...
Posted by Michael Wonder on 20 Feb 2023
Azafaros receives additional regulatory designations for AZ-3102 from FDA, EMA and MHRA
20 February 2023 - Azafaros today announced its progress in on-going interactions with health authorities regarding its lead asset, AZ-3102. ...
Posted by Michael Wonder on 20 Feb 2023
FDA accepts Valneva’s chikungunya vaccine license application for priority review
20 February 2023 - Valneva today announced that the US FDA has completed a filing review of its biologics license ...
Posted by Michael Wonder on 20 Feb 2023
Senators call on Medicare to offer broad coverage of Alzheimer’s treatments as public pressure grows
17 February 2023 - A group of 20 senators called on Medicare to take action now to offer seniors immediate access ...
Posted by Michael Wonder on 20 Feb 2023
US to select 10 costliest drugs for Medicare pricing negotiation
18 February 2023 - The US Government will select the 10 costliest prescription medicines to Medicare for negotiating prices with ...
Posted by Michael Wonder on 20 Feb 2023
TGA grants provisional approval to Moderna’s COVID-19 bivalent (Spikevax Bivalent Original/Omicron BA.4-5) booster dose vaccine
20 February 2023 - On 17 February, 2023, the TGA granted provisional approval to Moderna’s bivalent COVID-19 vaccine: elasomeran and ...